Corvus Pharmaceuticals IPO

3/23/2016

IPO

$70,500,000

We expect to use our existing capital resources and the net proceeds from this offering as follows: approximately $40 million to fund the ongoing clinical development of CPI-444, including our Phase 1/1b clinical trial; and the remainder to fund the preclinical development of our anti-CD73 adenosine production inhibitor, our adenosine A2B receptor antagonist, our ITK inhibitor and early-stage research and development of other programs and potential future development programs, potential in-licensing of technology or products, capital expenditures, working capital and other general corporate purposes. While we expect the majority of this amount will be allocated to our anti-CD73 adenosine production inhibitor, the allocation of funds among these product candidates will largely depend on their performance in preclinical trials, which we are unable to predict.

Publicly-held

Biopharmaceutical

863 Mitten Rd. 102
Burlingame, CA 94010
USA

Not Recorded

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer.